We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...
Read moreIn a joint report Lif, the New Therapeutics (NT) Council and representatives of the regions have pro...
Read moreWe explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreIdentification of current cost of oncology care treatment options.
Read moreWe investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...
Read moreAccording to Big health, randomised controlled trials have shown that 71% of patients who used Dayli...
Read moreAccording to the UICC, “priority will be given to medicines currently on the WHO Essential Medicin...
Read more